Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia

Targeted therapy has been the forefront of cancer treatment. Cancer immunotherapy is the most recent focus. In addition, novel immunotherapeutics targeting B cell receptor signaling (e.g., ibrutinib), T cell receptor ( e.g., CART19), and NK cells (e.g., AFM13) are being developed. This review summar...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Jingjing, Fu, Jiaping, Zhang, Mingzhi, Liu, Delong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4558758/
https://www.ncbi.nlm.nih.gov/pubmed/26337639
http://dx.doi.org/10.1186/s13045-015-0195-4
_version_ 1782388662949904384
author Wu, Jingjing
Fu, Jiaping
Zhang, Mingzhi
Liu, Delong
author_facet Wu, Jingjing
Fu, Jiaping
Zhang, Mingzhi
Liu, Delong
author_sort Wu, Jingjing
collection PubMed
description Targeted therapy has been the forefront of cancer treatment. Cancer immunotherapy is the most recent focus. In addition, novel immunotherapeutics targeting B cell receptor signaling (e.g., ibrutinib), T cell receptor ( e.g., CART19), and NK cells (e.g., AFM13) are being developed. This review summarized the new development in blinatumomab (MT103/MEDI-538), a first-in-class bispecific T engager (BiTE) antibody against CD19/CD3 in patients with relapsed/refractory precursor B cell acute lymphoid leukemia.
format Online
Article
Text
id pubmed-4558758
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-45587582015-09-04 Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia Wu, Jingjing Fu, Jiaping Zhang, Mingzhi Liu, Delong J Hematol Oncol Review Targeted therapy has been the forefront of cancer treatment. Cancer immunotherapy is the most recent focus. In addition, novel immunotherapeutics targeting B cell receptor signaling (e.g., ibrutinib), T cell receptor ( e.g., CART19), and NK cells (e.g., AFM13) are being developed. This review summarized the new development in blinatumomab (MT103/MEDI-538), a first-in-class bispecific T engager (BiTE) antibody against CD19/CD3 in patients with relapsed/refractory precursor B cell acute lymphoid leukemia. BioMed Central 2015-09-04 /pmc/articles/PMC4558758/ /pubmed/26337639 http://dx.doi.org/10.1186/s13045-015-0195-4 Text en © Wu et al. 2015 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Review
Wu, Jingjing
Fu, Jiaping
Zhang, Mingzhi
Liu, Delong
Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia
title Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia
title_full Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia
title_fullStr Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia
title_full_unstemmed Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia
title_short Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia
title_sort blinatumomab: a bispecific t cell engager (bite) antibody against cd19/cd3 for refractory acute lymphoid leukemia
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4558758/
https://www.ncbi.nlm.nih.gov/pubmed/26337639
http://dx.doi.org/10.1186/s13045-015-0195-4
work_keys_str_mv AT wujingjing blinatumomababispecifictcellengagerbiteantibodyagainstcd19cd3forrefractoryacutelymphoidleukemia
AT fujiaping blinatumomababispecifictcellengagerbiteantibodyagainstcd19cd3forrefractoryacutelymphoidleukemia
AT zhangmingzhi blinatumomababispecifictcellengagerbiteantibodyagainstcd19cd3forrefractoryacutelymphoidleukemia
AT liudelong blinatumomababispecifictcellengagerbiteantibodyagainstcd19cd3forrefractoryacutelymphoidleukemia

Ejemplares similares